Improved cardiorenal prognosis in diabetic nephropathy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Nephrology
Link
http://www.nature.com/articles/nrneph.2014.238.pdf
Reference10 articles.
1. de Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921–927 (2004).
2. Schmieder, R. E. et al. Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. Diabetologia 57, 2019–2029 (2014).
3. Andresdottir, G. et al. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care 37, 1660–1667 (2014).
4. Gaede, P., Lund-Andersen, H., Parving, H.-H. & Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580–591 (2008).
5. Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990–2010. N. Engl. J. Med. 370, 1514–1523 (2014).
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of multifactorial intensive treatment in patients with diabetic kidney disease: A meta‐analysis with trial sequential analysis;Diabetes, Obesity and Metabolism;2023-05-08
2. Randomized trial of an intensified, multifactorial intervention in patients with advanced‐stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan);Journal of Diabetes Investigation;2020-08-08
3. NGAL and SMAD1 gene expression in the early detection of diabetic nephropathy by liquid biopsy;Journal of Clinical Pathology;2020-03-17
4. Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy;Kidney International;2019-10
5. Atrasentan alleviates high glucose-induced podocyte injury by the microRNA-21/forkhead box O1 axis;European Journal of Pharmacology;2019-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3